CD274 and Ewing sarcoma: Molecular profiling on 35 DSRCTs sampled from patients having surgery for DSRCT (Caris Life Sciences, Phoenix, AZ) that were compared with Ewing sarcoma revealed low immunogenicity (<10 mutations/Mb) and low frequency of actionable mutations including PD-L1 in both tumor types.